GynecologyGynecology2079-56962079-5831Consilium Medicum3008110.26442/2079-5696_2018.3.48-51UnknownProgesterone contraceptives: a place in practical gynecology (to practitioner aid)DobrokhotovaY Ekatyanikitina@mail.ruBorovkovaE Ikatyanikitina@mail.ruZalesskayaS A-N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation15062018203485109042020Copyright © 2018, Consilium Medicum2018Progesterone-containing contraceptives do not have a significant impact on metabolic processes and can be prescribed to patients with systemic (diabetes mellitus, obesity) and other diseases. Desogestrel is a part of oral preparations in a dose of 75 mcg. The main mechanism of its contraceptive action is Suppression of ovulation (in 97% of cases). The frequency of pregnancy is 0.17 for 100 women-years. Progesterone-containing contraceptives should not be considered, as preparations of the second choice when deciding on the issue of family planning. According to the recommendations of the Center for Disease Control and Prevention organization of health, desogestrel is an acceptable contraceptive option for women with somatic diseases, defined tumor pathology and thrombotic states in the anamnesis.oral contraceptionprogesteronedesogestrelprogestin oral contraceptiveslactationоральная контрацепцияпрогестерондезогестрелпрогестиновые оральные контрацептивылактация[Kaunitz A.M. Revisiting progestin-only OCs. Contemp Ob Gyn 1997; 91.][World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th Edition, World Health Organization, 2015.][Benagiano G, Primiero F.M. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann NY Acad Sci 2003; 997: 163.][Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008; 34: 237.][Speroff L, Darney P. A Clinical Guide for Contraception, 4th ed, Williams and Wilkins, Baltimore 2005.][Lebech P.E, Svendsen P.A, Ostergaard E, Koch F. The effects of small doses of megestrol acetate on the cervical mucus. Acta Obstet Gynecol Scand 1969; 48 (Suppl. 3): 22.][Wright S.W, Fotherby K, Fairweather F. Effect of daily small doses of Norgestrel on ovarian function. J Obstet Gynaecol Br Commonw 1970; 77: 65.][Trussell J. Contraceptive failure in the United States. Contraception 2011; 83: 397.][Vessey M.P, Lawless M, Yeates F et al. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann 1985; 10: 117.][Curtis K.M, Jatlaoui T.C, Tepper N.K et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65: 1.][Lopez L.M, Edelman A, Chen M et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2013: CD008815.][MacGregor E.A. Contraception and headache. Headache 2013; 53: 247.][Belsey E.M. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38: 181.][Hussain S.F. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69: 89.][Godsland I.F, Crook D, Simpson R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375.][Winkler U.H. Blood coagulation and oral contraceptives. A critical review. Contraception 1998; 57: 203.][Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57: 315.][Heinemann L.A, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67.][Gomes M.P, Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164: 1965.][Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257.][Bergendal A, Persson I, Odeberg J et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124: 600.][Tepper N.K, Whiteman M.K, Marchbanks P.A et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception 2016; 94: 678.][ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453.][Curtis K.M, Tepper N.K., Jatlaoui T.C et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65: 1.][Dunson T.R, McLaurin V.L, Grubb G.S, Rosman A.W. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception 1993; 47: 23.][Kjos S.L, Peters R.K, Xiang A et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280: 533.]